To the Editor: Rosenthal (April 24 issue)1 presents a hypothetical case of malaria and states that there is “major concern” about the timeliness of artesunate availability because it is available rapidly only for hospitals that are near the 20 Centers for Disease Control and Prevention (CDC) quarantine stations. Artesunate is stocked at 8 of the 20 stations, which are located at major U.S. airports. To date, the timeliness of the provision of artesunate has been quite reasonable. Among the actual cases of the disease, on average it has taken only 7 hours (range, 3.5 to 15.5) from the time of the request for artesunate until the patient receives the first dose; 73% of the patients treated have been in hospitals that are not near CDC quarantine stations (average distance, 480 miles [772 km]; range, 66 to 1448 [106 to 2330]). To date, all patients treated according to this protocol have recovered. The CDC will continue to provide artesunate until it becomes a Food and Drug Administration (FDA)–approved, commercially available product and hospitals can maintain their own supply. Meanwhile, the current system can provide artesunate rapidly, and health care providers should be encouraged to access this medicine for the treatment of severe malaria.